AI-generated summary
The authors tested whether citalopram, an antidepressant, prevents relapse compared with placebo in 282 people with seasonal affective disorder who had responded to one week of light therapy. Over a 15-week continuation phase, citalopram was significantly better than placebo on two depression scales (HAM-D6 and Melancholia Scale), but not on the others.
- Participants
- 282
- Who or what was studied
- Patients with Seasonal Affective Disorder (SAD) who responded to 1 week of light therapy
- Limits stated in the abstract
- The abstract reports differences as statistically significant on only two of four scales, and it does not describe the study's design details or follow-up beyond the 15-week continuation phase.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Placebo-controlled, Statistical significance, Depression, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.